RLMD Relmada Therapeutics Inc

Relmada Therapeutics to Present at Jefferies London Healthcare Conference

Relmada Therapeutics to Present at Jefferies London Healthcare Conference

Conference being held November 19-21, 2024

CORAL GABLES, Fla., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, “the Company”), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer (CEO), will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024.

Jefferies London Healthcare Conference details:

Presentation:Wednesday, November 20, 2024 at 12:00 PM GMT
Speaker:Sergio Traversa, CEO
Registration:
  

The replay of the webcast will be available on the “For Investors/Events” page of the Relmada website for 90 days following the conference.                 

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Relmada's experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada's lead program, REL-1017, is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. The Company is also developing REL-P11, a proprietary low-dose psilocybin, as an investigational agent for metabolic disease. Learn more at .

Investor Contact:

Tim McCarthy

LifeSci Advisors

Media Inquiries:

Corporate Communications



EN
19/11/2024

Underlying

RLMDRelmada Therapeutics Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Relmada Therapeutics Inc

 PRESS RELEASE
Free
RLMD Relmada Therape...

Relmada Therapeutics Reports Second Quarter 2025 Financial Results and...

Relmada Therapeutics Reports Second Quarter 2025 Financial Results and Announces NDV-01 6-Month Follow-up Safety and Efficacy Data in NMIBC 6-month follow-up for NDV-01 showed a 91% overall response rate at any time in non-muscle invasive bladder cancer, with good overall safety Enrollment in the Phase 2 study for NDV-01 continues, with updates expected at 9 and 12 month data follow-up. Preparations underway to start Phase III registration trial in 1H 2026 Expecting to initiate a Phase 2 study for sepranolone in Prader-Willi syndrome in 1H 2026 Conference Call and Webcast Today at 4:30 P...

August 7, 2025 1 EN
 PRESS RELEASE
Free
RLMD Relmada Therape...

Relmada Therapeutics to Report Second Quarter 2025 Financial Results o...

Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025 CORAL GABLES, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced plans to host a conference call and webcast on Thursday, August 7, 2025 at 4:30 PM ET to discuss financial results for the second quarter ended June 30, 2025 and recent business progress. Conference Call and Webcast Information: Dat...

July 31, 2025 1 EN
 PRESS RELEASE
Free
RLMD Relmada Therape...

Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan...

Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01 Dr. Lotan’s distinguished expertise in bladder cancer care and clinical development brings further scientific acumen to Relmada’s NDV-01 program Phase 3 trial for NDV-01 expected to begin in H1 2026 CORAL GABLES, Fla., July 15, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications...

July 15, 2025 1 EN
 PRESS RELEASE
Free
RLMD Relmada Therape...

Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-...

Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology Dr. Pruthi brings vast clinical development experience advancing novel therapies for NMIBC to Relmada and the NDV-01 program Phase 3 trial for NDV-01 expected to begin in H1 2026 CORAL GABLES, Fla., June 17, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced the appointment of Raj S. Pruthi, MD as Chief Med...

June 17, 2025 1 EN
 PRESS RELEASE
Free
RLMD Relmada Therape...

Relmada Therapeutics Reports First Quarter 2025 Financial Results and ...

Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update Positive initial Phase 2 proof-of-concept data for NDV-01 at AUA 2025 showing a 90% overall response rate at any time in non-muscle invasive bladder cancer (US prevalence 600K patients) The Phase 2 study for NDV-01 continues with updates at 6, 9 and 12 month data follow-up over the course of 2025. Plans to start Phase III registration trial in H1 2026 Expecting to initiate a Phase 2 study for sepranolone in Prader-Willi syndrome in H1 2026 (US prevalence 20,000 patients) Conference Call and Web...

May 12, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch